Skip to main navigation
Skip to search
Skip to main content
Icahn School of Medicine at Mount Sinai Home
Help & FAQ
Link opens in a new tab
Search content at Icahn School of Medicine at Mount Sinai
Home
Profiles
Research units
Publications & Research Outputs
Press/Media
Enhancing NA immunogenicity through novel VLP designs.
Leticia Guzman Ruiz
, Zollner Alexander M
, Hoxie Irene
, Küchler Jan
, Hausjell Christina
, Mesurado Tomas
, Krammer Florian
, Alois Jungbauer
, Patricia Pereira Aguilar
, Klausberger Miriam
, Grabherr Reingard
Research output
:
Contribution to journal
›
Article
›
peer-review
4
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Enhancing NA immunogenicity through novel VLP designs.'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Immunology and Microbiology
Immunogenicity
100%
Virus-Like Particle
100%
Promoter Region
75%
Hemagglutinin
75%
Hemagglutinin-Neuraminidase
75%
Glycoprotein
50%
Epitope
50%
Influenza Vaccine
50%
Influenza A Virus (H1N1)
50%
Influenzavirus A
50%
Baculoviridae
50%
Human Immunodeficiency Virus 1
25%
Wild Type
25%
Antibody Response
25%
B Cell
25%
Titer
25%
Mouse Model
25%
Virus Hemagglutinin
25%
Influenza
25%
Low Drug Dose
25%
Affinity Chromatography
25%
Ultracentrifugation
25%
Insect Cell
25%
Gene Expression System
25%
Amino Acid
25%
Keyphrases
Immunogenicity
100%
Neuraminidase
100%
Virus-like
100%
Particle Design
100%
Hemagglutinin
27%
Hemagglutinin-neuraminidase
27%
Epitope
18%
Influenza Vaccine
18%
Influenza Virus
18%
H1N1
18%
Reactive Antibodies
18%
Neuraminidase Stalk
18%
Human Immunodeficiency Virus Type 1 (HIV-1)
9%
B Cells
9%
Glycoprotein
9%
Surface Glycoprotein
9%
Mouse Model
9%
Antibody Response
9%
Vaccination
9%
Antibody Titer
9%
Amino Acids
9%
New York
9%
Vaccine Candidate
9%
Neuraminidase Activity
9%
Protective Antibodies
9%
Ultracentrifugation
9%
Baculovirus
9%
Process-based
9%
Vaccine Preparation
9%
Heparin Affinity Chromatography
9%
Lateral Surface
9%
Downstream Process
9%
Baculovirus-insect Cell System
9%
GP64
9%
Capto Core 700
9%
Cross-reactive Antibodies
9%
Next Generation Influenza Vaccines
9%